IDERA PHARMACEUTICALS, INC. Human Resources Contracts & Agreements
65 Contracts & Agreements
- Bonus & Incentive Agreements (25 contracts)
- Change of Control Agreements (3)
- Compensation Agreements (6)
- Consulting Agreements (10)
- Employment Agreements (15)
- Separation Agreements (6)
- Executive Separation Agreement, dated as of August 15, 2023, entered into by and between Aceragen, Inc. and John Taylor (Filed With SEC on August 16, 2023)
- Amendment No. 1 to Executive Transition and Separation Agreement, by and among Daniel Soland and Aceragen, Inc., dated February 10, 2023 (Filed With SEC on April 13, 2023)
- Amendment No. 1 to Executive Transition and Separation Agreement, by and among Vincent Milano and Aceragen, Inc., dated February 10, 2023 (Filed With SEC on April 13, 2023)
- Form of Nonstatutory Stock Option Agreement (Non-Employee Directors) granted under the 2022 Stock Incentive Plan (Filed With SEC on April 13, 2023)
- Form of Nonstatutory Stock Option Agreement granted under the 2022 Stock Incentive Plan (Filed With SEC on April 13, 2023)
- Form of Incentive Stock Option Agreement granted under the 2022 Stock Incentive Plan (Filed With SEC on April 13, 2023)
- The Idera Pharmaceuticals, Inc. 2022 Stock Incentive Plan (Filed With SEC on January 13, 2023)
- First Amendment to Aceragen, Inc. 2021 Stock Incentive Plan Form of Stock Option Agreement (Filed With SEC on November 14, 2022)
- Aceragen, Inc. 2021 Stock Incentive Plan and Forms of Award Agreements (Filed With SEC on November 14, 2022)
- Executive Transition and Separation Agreement by and among Daniel Soland and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)
- Employment Continuation and Retention Bonus Letter Agreement by and among Bryant Lim and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)
- Employment Continuation and Retention Bonus Letter Agreement by and among John Kirby and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)
- Executive Transition and Separation Agreement by and among Vincent Milano and Idera Pharmaceuticals, Inc., dated September 28, 2022 (Filed With SEC on September 30, 2022)
- Amendment to the Idera Pharmaceuticals, Inc. 2013 Stock Incentive Plan (Filed With SEC on June 24, 2022)
- Consulting Agreement, dated May 18, 2021, between the Company and Elizabeth Tarka, M.D (Filed With SEC on May 18, 2021)
- Severance and Change of Control Agreement, dated February 19, 2021, by and between the Company and Daniel Soland (Filed With SEC on March 1, 2021)
- Employment Offer Letter, dated November 16, 2020, by and between Idera Pharmaceuticals, Inc. and Daniel Soland (Filed With SEC on March 1, 2021)
- Consulting Agreement, dated December 29, 2020, between the Company and R. Clayton Fletcher (Filed With SEC on January 5, 2021)
- Form of Performance-Based Restricted Stock Agreement under the 2013 Stock Incentive Plan (Filed With SEC on October 29, 2020)
- Amendment to Severance and Change of Control Agreement, dated January 27, 2020, by and between the Company and Dr. Jonathan Yingling (Filed With SEC on January 27, 2020)
- Amendment to Employment Agreement, dated January 10, 2020, by and between the Company and Vincent J. Milano (Filed With SEC on January 15, 2020)
- Employment Offer Letter, dated June 26, 2019, by and between Idera Pharmaceuticals, Inc. and Elizabeth Tarka (Filed With SEC on August 8, 2019)
- Form of Restricted Stock Agreement under the 2013 Stock Incentive Plan (Filed With SEC on August 8, 2019)
- Employment Offer Letter, dated October 15, 2015, by and between Idera Pharmaceuticals, Inc. and John J. Kirby (Filed With SEC on March 6, 2019)
- Employment Offer Letter, dated August 20, 2018, by and between Idera Pharmaceuticals, Inc. and Bryant D. Lim (Filed With SEC on November 6, 2018)
- Director Compensation Program (Filed With SEC on March 7, 2018)
- Employment Letter, dated February 2, 2017, by and between Idera Pharmaceuticals, Inc. and Jonathan Yingling (Filed With SEC on March 7, 2018)
- Employment Letter, dated November 11, 2015 by and between Idera Pharmaceuticals, Inc. and Joanna Horobin (Filed With SEC on March 7, 2018)
- SEPARATION AGREEMENT AND RELEASE OF CLAIMS (Filed With SEC on August 7, 2017)
- AMENDMENT TO IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN, AS AMENDED (Filed With SEC on June 9, 2017)
- SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on May 4, 2017)
- AMENDMENT TO IDERAPHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN, AS AMENDED (Filed With SEC on June 11, 2015)
- CONSULTING AGREEMENT (Filed With SEC on May 11, 2015)
- IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on June 13, 2014)
- Director Compensation Program (Filed With SEC on May 12, 2014)
- IDERA PHARMACEUTICALS, INC. Non-Employee Director Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on July 29, 2013)
- IDERA PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on July 29, 2013)
- IDERA PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Filed With SEC on July 29, 2013)
- IDERA PHARMACEUTICALS, INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on July 29, 2013)
- AMENDMENT TO THE CONSULTING SERVICES AGREEMENT (Filed With SEC on March 14, 2012)
